sBioMed announces appointment of new CEO

sBioMed, a developer of infection control products, recently announced that it has appointed a new chief executive officer.

Stephen P. MacMillan, the former chairman and CEO of Stryker, has joined the company as its chairman, CEO and a partial owner, according to

"With Steve's leadership, we can help eliminate Healthcare-Associated Infections globally," Brian Larson, sBioMed's founder said, reports.

The company is known predominantly for its C. difficile sporicide and broad-spectrum disinfectant, STERIPLEX SD. STERPLEX Ultra, which uses a similar technology, is the only EPA-registered product to kill anthrax spores.

"It's rare to find a product with such revolutionary potential," MacMillan said, reports. "STERIPLEX SD will save lives, improve healthcare delivery and protect caregivers, while reducing healthcare costs and preserving the environment. I'm also excited about the chance to work with the sBioMed team to build a very special global company based in Utah."

Beginning in 2013, HAIs will no longer be reimbursed, which will give hospitals a greater incentive to eliminate infections such as C. difficile. Every year, HAIs cost the U.S. healthcare system billions of dollars and have become a leading cause of death in the United States. sBioMed hopes to be poised to take advantage of the changes.

"After a decade of research, over 500 studies and EPA-registration, we are excited to enter the full-scale commercialization process," Larson said, reports.